Cancer-associated fibroblast-derived lactate drives cholangiocarcinoma progression via H4K12la-mediated oxidative phosphorylation activation

Background: Cholangiocarcinoma (CCA) is a highly aggressive malignancy, and chemoresistance is a major cause of poor prognosis. This study aimed to elucidate the molecular mechanisms driving CCA progression from a tumor microenvironment perspective and to develop novel strategies to enhance chemosensitivity. Methods: Single-cell RNA-seq, untargeted metabolomics, and proteomics were used to identify the source of lactate in the CCA microenvironment and the metabolic reprogramming of cancer-associated fibroblasts (CAFs). To evaluate the impact of CAF-derived lactate on prognosis, we performed AAV-mediated MCT4 knockdown followed by hydrodynamic injection to induce a CCA model. Co-culture models were combined with genome-wide CUT&Tag, MeRIP-seq, and RIP-seq to resolve epigenetic and post-transcriptional regulatory mechanisms. The antitumor effects of 7ACC1 (a small molecule reported to inhibit lactate uptake), alone or in combination with gemcitabine, were assessed in subcutaneous and orthotopic liver xenograft models. Results: CAFs undergo glycolytic reprogramming, resulting in aberrant lactate accumulation. Mechanistically, CAF-derived lactate induces H4K12 lactylation (H4K12la) in CCA cells, which in turn activates the IGF2BP3/ATF3 axis to upregulate oxidative phosphorylation and promote tumor progression. The lactate shuttle inhibitor 7ACC1, combined with gemcitabine, exerts promising antitumor effects. Clinically, high levels of MCT4, α SMA, and H4K12la are associated with poor prognosis in patients with CCA. Conclusions: These findings reveal that CAFs drive CCA progression via lactate-induced H4K12la, which activates the IGF2BP3/ATF3 axis. The findings provide a preclinical rationale for further evaluation of lactate-uptake-targeting strategies in combination with gemcitabine for CCA.

Authors

Institutions

Publication Details

Journal
Clinical and Molecular Hepatology
Published
2026-11-17
DOI
https://doi.org/10.3350/cmh.2026.0591
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cancer-associated fibroblast-derived lactate drives cholangiocarcinoma progression via H4K12la-mediated oxidative phosphorylation activation

Yananlan Chen, Shenye Shao, Kai Cao, Shuochen Liu et al.
5 links
Clinical and Molecular Hepatology
Cholangiocarcinoma and Gallbladder Cancer Studies
article

Cancer-associated fibroblast-derived lactate drives cholangiocarcinoma progression via H4K12la-mediated oxidative phosphorylation activation

Yananlan Chen, Shenye Shao, Kai Cao, Shuochen Liu, Xiangcheng Li, Xiao Xu, Changxian Li, Ziyang Wang, Ji Cui, Jiawei Zhang
article en

Abstract

Background: Cholangiocarcinoma (CCA) is a highly aggressive malignancy, and chemoresistance is a major cause of poor prognosis. This study aimed to elucidate the molecular mechanisms driving CCA progression from a tumor microenvironment perspective and to develop novel strategies to enhance chemosensitivity. Methods: Single-cell RNA-seq, untargeted metabolomics, and proteomics were used to identify the source of lactate in the CCA microenvironment and the metabolic reprogramming of cancer-associated fibroblasts (CAFs). To evaluate the impact of CAF-derived lactate on prognosis, we performed AAV-mediated MCT4 knockdown followed by hydrodynamic injection to induce a CCA model. Co-culture models were combined with genome-wide CUT&Tag, MeRIP-seq, and RIP-seq to resolve epigenetic and post-transcriptional regulatory mechanisms. The antitumor effects of 7ACC1 (a small molecule reported to inhibit lactate uptake), alone or in combination with gemcitabine, were assessed in subcutaneous and orthotopic liver xenograft models. Results: CAFs undergo glycolytic reprogramming, resulting in aberrant lactate accumulation. Mechanistically, CAF-derived lactate induces H4K12 lactylation (H4K12la) in CCA cells, which in turn activates the IGF2BP3/ATF3 axis to upregulate oxidative phosphorylation and promote tumor progression. The lactate shuttle inhibitor 7ACC1, combined with gemcitabine, exerts promising antitumor effects. Clinically, high levels of MCT4, α SMA, and H4K12la are associated with poor prognosis in patients with CCA. Conclusions: These findings reveal that CAFs drive CCA progression via lactate-induced H4K12la, which activates the IGF2BP3/ATF3 axis. The findings provide a preclinical rationale for further evaluation of lactate-uptake-targeting strategies in combination with gemcitabine for CCA.

Clinical and Molecular Hepatology
Nanjing University of Chinese Medicine (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Jiangsu Province Hospital (CN), Wuxi People's Hospital (CN), Nanjing Medical University (CN)
Good health and well-being
Cholangiocarcinoma and Gallbladder Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon